Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer's Disease from the U.S. Patent and Trademark Office

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that the Company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) regarding Cyclo Therapeutics’ U.S. Patent Application No. 17/289,137 titled, “Methods for Treating Alzheim ...